POM-V Prescription Required

Cubarmix Equi 400 mg/g + 80 mg/g Oral Powder for Horses

Active ingredients: Sulfadiazine, Trimethoprim

Form

Powder

Species

Horses

Manufacturer

Dopharma Research B.V.

VMD MA No.

28365/5009

What it's used for

Norodine 24 Injectable Solution is indicated in the treatment of systemic infections caused by or associated with organisms sensitive to the Trimethoprim:S...

Full indications, dosage and side effects ↓

View official SPC (PDF)

The prescription itself has a price. See what practices near you charge for a consultation and the written prescription fee.

Paying less for Sulfadiazine + Trimethoprim

1

Ask your vet for a written prescription

They must provide one on request. Under the CMA Order the fee is capped at £21 from 2027.
2

Fill it at a registered online retailer

The CMA found online pharmacies 50–60% cheaper than practice dispensing on common medicines — typically £200–£300 a year.

Your prescription rights → VMD register of retailers →

Prescription required

Your vet must provide a written prescription on request. You can then purchase from any licensed online retailer.

Clinical information

Cubarmix Equi 400 mg/g + 80 mg/g Oral Powder for Horses — SPC Details

Source: VMD Summary of Product Characteristics (SPC). Last updated 27 Mar 2026.

Norodine 24 Injectable Solution is indicated in the treatment of systemic
infections caused by or associated with organisms sensitive to the
Trimethoprim:Sulfadiazine combination. The spectrum of activity includes both
Gram-positive and Gram-negative organisms including:
Actinobacilli
Actinomycae
Bordetella spp
Brucella
Corynebacteria
Escherichia coli
Haemophilus spp
Klebsiella spp
Pasteurella spp

Revised: January 2026
AN: 03001/2025
Pneumococci
Proteus
Salmonella spp
Staphylococci
Streptococci
Vibrio

The recommended dose per administration is 30 mg combined active ingredients per
kg body weight, meaning 25 mg sulfadiazine and 5 mg trimethoprim per kg body
weight or 62.5 mg veterinary medicinal product/kg body weight (equivalent to 12.5 g
powder per 200 kg of BW), administered once daily for 5 days.
To ensure a correct dosage, body weight should be determined as accurately as
possible.
The use of suitably calibrated weighing equipment is recommended.
Mix with a small quantity of feed. It is recommended that other feed be withdrawn
until medicated feed has been consumed.
The veterinary medicinal product is to be administered only for the treatment of
individually fed animals.

Do not use in cases of hypersensitivity to the active substances (or any other
sulfonamide) or to any of the excipients.
Do not use in horses with severe liver parenchymal damage or kidney damage.
Do not use in horses with blood dyscrasias or cardiac arrhythmias.

Horses:
Common
(1 to 10 animals / 100 animals
treated):
Digestive tract disorder (e.g. loose stool,
diarrhoea, colitis)
Undetermined frequency
(cannot be estimated from the
available data)
Hypersensitivity reaction (e.g. urticaria)
Inappetence
Hepatic disorder
Renal disorder, renal tubular disorder
Haematologic effects (e.g. anaemia,
thrombocytopenia, or leucopenia)
Haematuria, crystalluria
Treatment should be discontinued and symptomatic treatment initiated, if needed.
tubular obstruction
Reporting adverse events is important. It allows continuous safety monitoring of a
veterinary medicinal product. Reports should be sent, preferably via a veterinarian,
to either the marketing authorisation holder or its local representative or the national
competent authority via the national reporting system. See the package leaflet or
immediate packaging for respective contact details.

In case of infections involving purulent conditions, trimethoprim-sulfonamides
combinations are not recommended due to a diminished efficacy under such
conditions.
AN: 03159/2024 & 03557/2024
Cross-resistance has been shown between sulfadiazine and other sulfonamides.
Use of the veterinary medicinal product should be carefully considered when
susceptibility testing has shown resistance to combinations of trimethoprim with
other sulfonamides because its effectiveness may be reduced.

Special precautions for safe use in the target species:
The use in horses under 1 year old should be avoided.
Throughout the treatment, animals should have free access to drinking water to
avoid possible crystalluria.
Use of the veterinary medicinal product should be based on identification and
susceptibility testing of the target pathogen(s). If this is not possible, therapy should
be based on epidemiological information and knowledge of susceptibility of the target
pathogens at farm level, or at local/regional level.
Use of the veterinary medicinal product should be in accordance with official,
national and regional antimicrobial policies.
Narrow spectrum antibiotic therapy with a lower risk of antimicrobial resistance
selection should be used for first line treatment where susceptibility testing suggests
the likely efficacy of this approach.
Special precautions to be taken by the person administering the veterinary medicinal
product to animals:

This veterinary medicinal product may cause hypersensitivity reactions following
inhalation, ingestion or skin contact. Hypersensitivity to sulfonamides may lead to
cross reactions with other antibiotics. Allergic reactions to sulfonamides may
occasionally be serious. People with known hypersensitivity to sulfadiazine (or other
sulfonamides) or trimethoprim should avoid contact with the veterinary medicinal
product.
The veterinary medicinal product may be harmful in case of accidental ingestion
including hand-to-mouth contact, inhalation or accidental contact with unprotected
skin and eyes. This veterinary medicinal product may cause irritation to skin, eyes
and respiratory system.
Care should be taken not to inhale any dust and contact with skin and eyes should
be avoided. Take care to avoid accidental ingestion, especially by children.
Personal protective equipment consisting of rubber gloves, goggles and a dust mask
(disposable half-mask respirator conforming to EN149 or a non-disposable respirator
EN140 with a filter EN143) should be worn when mixing or handling the veterinary
medicinal product. Do not smoke, eat or drink while handling the veterinary medicinal
product. The veterinary medicinal product should be stored at a safe place out of the
reach and site of children.
AN: 03159/2024 & 03557/2024
In case of skin or eyes contact, rinse immediately with plenty of water. If you develop
symptoms following exposure such as a skin rash, you should seek medical advice
and show the physician this warning. Swelling of the face, lips or eyes or difficulty
with breathing are more serious symptoms and require urgent medical attention.
Wash hands after use.
Special precautions for the protection of the environment:
Not applicable.

Potentiated sulfonamides used in conjunction with alpha2-adrenoceptor agonists like
detomidine are known to be able to cause fatal arrhythmias in the horse.
Do not administer concurrently with para-aminobenzoic acid (PABA). Local
anaesthetics from the group of para-aminobenzoic acid esters (procaine,
benzocaine, tetracaine) can locally inhibit the effect of sulfonamides.

This veterinary medicinal product does not require any special temperature storage
conditions.
Store in the original package in order to protect from light.

Meat and offal: 6 months.
Not authorised for use in animals producing milk for human consumption.
AN: 03159/2024 & 03557/2024
4.

This information is sourced from the official Summary of Product Characteristics (SPC) published by the Veterinary Medicines Directorate (VMD). It is provided for informational purposes only and does not replace professional veterinary advice. Always consult your vet before administering any medication.